Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 195

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort

Lee, Woo-Jin, Lee, Soon-Tae, Byun, Jung-Ick, Sunwoo, Jun-Sang, Kim, Tae-Joon, Lim, Jung-Ah, Moon, Jangsup, Lee, Han Sang, Shin, Yong-Won, Lee, Keon-Joo, Kim, Soyun, Jung, Keun-Hwa, Jung, Ki-Young, Chu, Kon, Lee, Sang Kun · 2016 · Neurology

Abstract

OBJECTIVE: To determine efficacy and safety of rituximab treatment as a second-line immunotherapy treatment for autoimmune limbic encephalitis (ALE) and to determine factors associated with functional improvement and favorable outcome following rituximab treatment. METHODS: We recruited 80 patients with ALE who were treated with rituximab as a second-line immunotherapy from the Korea Autoimmune Synaptic and Paraneoplastic Encephalitis Registry and reviewed 81 patients without rituximab as a control. We grouped patients according to the detection or type of antibodies; in addition, we evaluated clinical, laboratory, first-line immunotherapy, and rituximab treatment profiles and defined main outcomes as improvements on the modified Rankin Scale (mRS) score and a favorable mRS score (0-2) at the last follow-up. RESULTS: Functional improvement occurred more frequently in the rituximab group compared to the control group. In the rituximab group, 30 (37.5%) patients had synaptic autoantibodies, 15 (18.8%) in the paraneoplastic autoantibodies, and 35 (43.8%) were antibody-negative. The effect of rituximab was the same regardless of autoantibody status. Additional monthly rituximab therapy and partial response to first-line immunotherapies were associated with mRS score improvements, as well as favorable mRS scores. mRS scores of 4-6 as the worst neurologic status predicted an unfavorable mRS score. There were no reported serious infusion-related or infectious adverse effects of rituximab. CONCLUSIONS: Rituximab is effective and safe as a second-line immunotherapy for ALE, regardless of autoantibody status. Additional monthly rituximab therapy might potentiate the efficacy of rituximab. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that rituximab improves mRS scores for patients with autoimmune limbic encephalitis who fail first-line therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000002635

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 195

Metadata

Authors
Lee, W.-J., Lee, S.-T., Byun, J.-I., Sunwoo, J.-S., Kim, T.-J., Lim, J.-A., Moon, J., Lee, H. S., Shin, Y.-W., Lee, K.-J., Kim, S., Jung, K.-H., Jung, K.-Y., Chu, K., & Lee, S. K.
Venue
Neurology
Published
2016-05-03
Volume
86
Issue
18
Pages
1683-1691
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2319091176
Cited by
195
References
6
FWCI
12.66
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. https://app.cochat.ai/papers/10.1212/wnl.0000000000002635
The paper
Lee, W.-J., Lee, S.-T., Byun, J.-I., Sunwoo, J.-S., Kim, T.-J., Lim, J.-A., Moon, J., Lee, H. S., Shin, Y.-W., Lee, K.-J., Kim, S., Jung, K.-H., Jung, K.-Y., Chu, K., & Lee, S. K. (2016). Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. Neurology. https://doi.org/10.1212/wnl.0000000000002635

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.